Recently, the H1N1 flu has entered an epidemic phase, and there is a tight supply of the new anti-influenza drug "Sufuda" in some pharmacies. In response, Roche stated during a press conference that the company attaches great importance to ensuring the supply of "Sufuda" in the China market during the 2024-2025 flu season. Currently, the global production capacity of "Sufuda" is all geared towards the China market. At this stage, the supply of "Sufuda" in the China market is adequate. The company has gained access in approximately 7,000 hospitals nationwide and is steadily supplying major offline chain pharmacies in collaboration with partners. Furthermore, with the help of Internet Plus-Related Hospitals, patients can also purchase "Sufuda" on online platforms such as JD.com, Meituan, Alibaba, and Dingdang with a prescription. (Securities Times)